Monaco Asset Management SAM Boosts Stock Position in Novavax, Inc. $NVAX

Monaco Asset Management SAM lifted its stake in shares of Novavax, Inc. (NASDAQ:NVAX) by 73.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 400,000 shares of the biopharmaceutical company’s stock after buying an additional 170,000 shares during the quarter. Monaco Asset Management SAM’s holdings in Novavax were worth $3,468,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Novavax by 95.2% during the 1st quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $285,000 after acquiring an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after purchasing an additional 2,750 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Novavax in the 1st quarter valued at about $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Novavax by 16.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock worth $2,005,000 after purchasing an additional 44,105 shares in the last quarter. Finally, Strs Ohio bought a new stake in Novavax in the first quarter valued at about $167,000. Institutional investors own 53.04% of the company’s stock.

Novavax Trading Down 0.3%

Novavax stock opened at $9.20 on Friday. The firm has a 50-day moving average price of $8.01 and a two-hundred day moving average price of $7.96. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 5.14 and a beta of 2.58. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $10.64.

Wall Street Analysts Forecast Growth

NVAX has been the subject of several research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a research report on Monday, December 29th. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. TD Cowen reduced their price target on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 18th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus price target of $11.25.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.